.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Matthew B. Yurgelun, MD

Articles

Updates on Imaging-Based Pancreatic Cancer Surveillance for Individuals With Increased Genetic and Familial Risk

August 15th 2023

Recent years have brought tremendous progress in demonstrating that there is hope for improving mortality from pancreatic ductal adenocarcinoma through early detection.

Online Tool Estimates the Risk for Lynch Syndrome

February 5th 2019

Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.

Dr. Yurgelun Discusses Germline Testing in CRC

May 3rd 2017

Matthew B. Yurgelun, MD, assistant professor of Medicine, Harvard Medical School, and a researcher at the Dana-Farber Cancer Institute, discusses germline testing in colorectal cancer.

Dr. Matthew Yurgelun on Pathogenic Mutations in CRC

September 22nd 2016

Matthew B. Yurgelun, MD, Targeted Oncology, Yurgelun, Instructor in Medicine, Harvard Medical School, discusses a recent study which uncovered BRCA1 and BRCA2 mutations as possible risk markers for colorectal cancer.

Dr. Matthew Yurgelun on Next Steps in Understanding CRC Mutations

August 26th 2016